Table 1 Representative clinical trials of LNP-based mRNA for cancer vaccine
From: Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
Type of cancer | Name | Encoding | Strategy | References (NCT Number) |
|---|---|---|---|---|
Melanoma | mRNA-4157 | Personalized 20 TAAs | Monotherapy | NCT03897881 |
Solid Tumor | Monotherapy or combination with Pembrolizumab (αPD-1) | NCT03313778 | ||
Melanoma | Lipo-MERIT | TAAs (NY-ESO-1, Tyrosinase, MAGE-A3, and TPTE) | DC targeted and type I IFN-dependent immunotherapy | NCT02410733 |
Ovarian Cancer | W_ova1 | 3 TAAs | Combination with neo-adjuvant chemotherapy (OLIVIA) | NCT04163094 |
Triple-negative breast cancer (TNBC) | TNBC-MERIT | TAAs | Patient-specific liposome with RNA tailored to the personalized TAAs (IVAC_W_bre1_uID) | NCT02316457 |
De novo synthesized RNAs targeting up to 20 individual tumor mutations (IVAC_M_uID) | ||||
Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer | NCI-4650 | 20 different TAAs | Immunization | NCT03480152 |
Melanoma, Non-Small Cell Lung Cancer (NSCLC), Bladder Cancer, Colorectal Cancer, TNBC, Renal Cancer, Head and Neck Cancer, Other Solid Cancers | Autogene Cevumeran (RO7198457) | Neoantigen | Monotherapy or combination with Atezolizumab (αPD-L1) | NCT03289962 |
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer | mRNA-2416 | Human OX40L | Monotherapy or combination with Durvalumab (αPD-L1) | NCT03323398 |
Solid Tumor Malignancies, Lymphoma, TNBC, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, Urothelial Cancer | mRNA-2752 | Human OX40L, IL-23, and IL-36γ | Monotherapy or combination with Durvalumab | NCT03739931 |
Metastatic Neoplasm | SAR441000 | IL-12sc, IL-15sushi, IFNα-2b and GM-CSF | Monotherapy or combination with Cemiplimab (αPD-1) | NCT03871348 |
Solid Tumor and Cancer | MEDI1191 | IL-12 | Combination with Durvalumab (αPD-L1) | NCT03946800 |
Neoplasms Carcinoma, NSCLC, Pancreatic Neoplasms, Colorectal Neoplasms | mRNA-5671/V941 | G12D, G12V, G13D, and G12C | Monotherapy or combination with Pembrolizumab (αPD-1) | NCT03948763 |